Evidence map›Paper›PMID 41366030›Full record

Trial reportJournal of bone and mineral metabolism2026

Efficacy of zoledronic acid in peri-menopausal women with osteopenia.

Trupti Nagendra Prasad, L Romesh Sharma, Anil Bhansali, Sanjay Kumar Bhadada, Neelam Aggarwal, Tulika Singh, Naresh Sachdeva, Biona Devi Konsam, Vivek Premshankar Tiwari, Mintu Mani Baruah and 1 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of bone and mineral metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Trupti Nagendra Prasad *Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
L Romesh Sharma *Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Anil BhansaliDepartment of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Sanjay Kumar BhadadaDepartment of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Neelam AggarwalDepartment of Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Tulika SinghDepartment of Radiodiagnosis, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Naresh SachdevaDepartment of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Biona Devi KonsamDepartment of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Vivek Premshankar TiwariDepartment of Radiodiagnosis, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Mintu Mani BaruahDepartment of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Rama WaliaDepartment of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India. ramawaliapgimer@gmail.com.ORCID http://orcid.org/0000-0002-6633-923X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA significant proportion of bone loss per year occurs starting around 1-3 years before menopause. A number of fractures occur in the osteopenic range of bone mineral density (BMD). There are no recommendations for the treatment of osteopenic peri-menopausal women. We conducted this study to explore the utility of zoledronic acid in preserving bone health in this population. MATERIALS AND

methodsThis is a prospective single-blinded randomized controlled trial. A total of 60 peri-menopausal women and 30 postmenopausal women with osteopenia were enrolled. The peri-menopausal women were randomized to receive either zoledronic acid or placebo in a 1:1 ratio. All postmenopausal osteopenic women received zoledronic acid. Participants were followed up for 12 months. BMD and bone turnover markers (BTM) were assessed.

resultsAt the end of 12 months, there was a significant increase in lumbar spine BMD in the peri-menopausal and postmenopausal groups which received zoledronic acid. On further subcategorizing the T-score, the improvement in BMD was statistically significant in the group with a T-score of - 1.75 to - 2.5. In peri-menopausal women with osteopenia with a T-score of - 1.75 to - 2.5, a single infusion of zoledronic acid increased lumbar spine and femoral neck BMD and suppressed the high bone turnover. Zoledronic acid thus could be used for preserving bone density and preventing the risk of osteoporosis and fragility fractures in the future.

Indexed as

Bone Density Conservation AgentsBone Diseases, MetabolicDiphosphonatesImidazolesPerimenopauseBone DensityFemaleHumansLumbar VertebraeMiddle AgedProspective StudiesSingle-Blind MethodZoledronic AcidBone Density Conservation AgentsDiphosphonatesImidazolesZoledronic AcidBone lossOsteopeniaOsteoporosisPeri-menopauseZoledronic acid

Identifiers

PMID41366030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.